Profile: Athersys Inc (ATHX.OQ)
20 Jan 2017
Athersys, Inc., incorporated on June 7, 2005, is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its operations consist primarily of research and product development activities. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. MultiStem treatment enhances tissue repair and healing in multiple ways, including reducing inflammatory damage, protecting tissue that is at risk following acute or ischemic injury, and promoting formation of new blood vessels in regions of ischemic injury. These cells appear to be responsive to the environment in which they are administered, by homing to sites of injury and/or organs involved in injury response, and providing active disease response, while producing proteins that may provide benefit in both acute and chronic conditions.
In the neurological area, the Company evaluated in a completed Phase II trial the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI. The Company has also initiated a clinical study for the treatment of acute respiratory distress syndrome (ARDS), a serious immunological and inflammatory condition characterized by widespread inflammation in the lungs, in the United Kingdom and in the United States. In addition, the Company evaluated in a completed Phase I clinical study, the potential for MultiStem cell therapy to prevent or reduce graft-versus-host disease (GvHD) and other complications, and to provide supportive care to patients undergoing a hematopoietic stem cell transplant to treat leukemia or related conditions.
The Company's programs in the clinical development-stage include ischemic stroke, acute myocardial infarction, acute respiratory distress syndrome, hematopoietic stem cell transplant/GvHD and Inflammatory Bowel Disease (IBD). Its regenerative medicine programs focuses on MultiStem administration for the treatment of neurological injury as a result of acute or chronic conditions; treating damage from a heart attack, and acute pulmonary distress, IBD and hematopoietic stem cell (HSC) transplant support. In addition, the Company has developed pharmaceutical treatments for obesity, which are compounds designed to act by stimulating a key receptor in the brain that regulates appetite and food intake-the 5HT2c receptor. Its clinical candidates are developed as potent and selective orally administered compounds that stimulate the 5HT2c receptor.
The Company competes with Pfizer, Johnson & Johnson, Celgene Corporation, Mesoblast Limited, Aastrom Biosciences, Inc., Stem Cells Inc., Cytori Therapeutics, Inc., Pluristem Therapeutics, Inc., Arena Pharmaceuticals, Vivus, Inc., Orexigen, F. Hoffman - LaRoche Ltd., Bristol-Myers Squibb, Merck & Co., Inc., Sanofi, GlaxoSmithKline plc, and Eli Lilly and Company.
3201 Carnegie Ave
CLEVELAND OH 44115-2634